Chimera Research Group

previous arrow
next arrow
Slider

May 17th Biotech Update

It has been a pretty good week for the sector with a nice steady move higher.  It has not be an absolute straight line nor has it been dramatic one but a slow build higher is not too bad.  In some ways, this is better than an accelerating move as this provides more volume at […]

May 15th Biotech Update

This week has not been too bad for the sector. Perhaps my original thought about steady rates being good for the sector will actually pan out.  Of course, that all can change with the next CPI number of Fed talk and so we are still very tied to the broader rate environment (at least that […]

May 13th Biotech Update

While my idea that steady rates would provide some room for the sector to recover and potentially move higher is not quite working out.  Steady rates are not bad for the sector but I still think there are worries about the rate environment and perhaps we need to see a little more confidence that inflation […]

May 10th Biotech Update

Not the best of weeks but also not the worst of weeks.  It would have been ideal to get some momentum to the upside but grinding volume at this level is not awful for the longer term.  Of course, if the next move is significantly lower then this ends up being a level of resistance […]

Mailing List

Introduction

Overview

Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press

Slider

Log In

JoinLost Password?